Physician profile
Ryan L Colella
NPI 1265403737
$2,269.65
in general payments reported to CMS, 2019-2025
29 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $132 · 2021: $386 · 2022: $342 · 2023: $310 · 2024: $373 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,046.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $336.24 | 2019-2025 | Liletta |
| Astellas Pharma US INC | $334.80 | 2022-2025 | Veozah |
| Exeltis, USA INC. | $199.42 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $188.11 | 2021-2025 | |
| Coopersurgical, INC. | $109.50 | 2021-2025 | Paragard T 380a, Mara Console, Paragard T 380a |
| Pfizer INC. | $100.16 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $97.97 | 2023-2025 | Myfembree |
| Therapeuticsmd, INC. | $94.49 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $93.29 | 2020-2024 | Gardasil 9, Gardasil |
| Organon LLC | $82.69 | 2022-2025 | Nexplanon |
| Myovant Sciences INC. | $78.84 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.52 | 2023 | |
| Hologic Sales and Service, LLC | $51.77 | 2019-2022 | |
| Allergan, INC. | $50.63 | 2019-2020 | |
| Evofem Biosciences, INC. | $47.55 | 2021-2025 | Solosec, Phexx, Phexxi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $44.65 | 2025 | Intrarosa, Femlyv, Femring |
| Mylan Pharmaceuticals INC. | $41.96 | 2021-2022 | |
| Avion Pharmaceuticals | $41.42 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $36.61 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $27.77 | 2021 | |
| Lilly USA, LLC | $26.36 | 2019 | |
| Si-Bone, INC. | $20.27 | 2025 | |
| Shield Therapeutics INC | $19.55 | 2024 | |
| Medicem INC. | $14.43 | 2021 | |
| Duchesnay USA Incorporated | $14.33 | 2019 | |
| Sage Therapeutics, LLC | $14.07 | 2025 | Zurzuvae |
| Lupin INC. | $12.86 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.13 | 2019 | |
| Minerva Surgical, INC | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Colella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.